-
1.发明授权
公开(公告)号：US5804181A
公开(公告)日：1998-09-08
申请号：US452169
申请日：1995-05-26
申请人： Johann Eibl , Hans Peter Schwarz , Katalin Varadi
发明人： Johann Eibl , Hans Peter Schwarz , Katalin Varadi
CPC分类号： A61K38/36 , A61K38/482
摘要： A pharmaceutical preparation for the prevention and treatment of blood coagulation disorders is described which is characterized in that it comprises Factor V as a native protein, derivative and/or fragment thereof and Protein S in suitable pharmaceutical carrier.
摘要翻译： 描述了用于预防和治疗凝血障碍的药物制剂，其特征在于其包含作为天然蛋白质的因子V，其衍生物和/或片段以及合适的药物载体中的蛋白S。
-
公开(公告)号：US5863896A
公开(公告)日：1999-01-26
申请号：US555423
申请日：1995-11-09
申请人： Jan Rosing , Guido Tans , Katalin Varadi , Hans Peter Schwarz
发明人： Jan Rosing , Guido Tans , Katalin Varadi , Hans Peter Schwarz
CPC分类号： G01N33/86 , A61K38/36 , C12Q1/56 , G01N2333/745 , G01N2333/96461 , G01N2333/96463 , G01N2405/04
摘要： The present invention provides methods, reagents, and test kits for evaluating the effect of a test composition on APC response by employing factor Va.sup.R506Q Methods and compositions for treating patients suffering from reduced APC response are also provided.
摘要翻译： 本发明提供了通过使用因子VaR506Q来评估测试组合物对APC反应的影响的方法，试剂和测试试剂盒。还提供了用于治疗患有APC反应降低的患者的组合物。
-
公开(公告)号：US5643739A
公开(公告)日：1997-07-01
申请号：US432018
申请日：1995-05-01
申请人： Katalin Varadi , Hans Peter Schwarz , Hartmut Lang , Berta Moritz
发明人： Katalin Varadi , Hans Peter Schwarz , Hartmut Lang , Berta Moritz
CPC分类号： C12Q1/56 , G01N2333/96444 , G01N2333/9645 , G01N2333/96461 , G01N2333/974 , G01N2405/04 , Y10S435/81 , Y10S436/808 , Y10S514/834
摘要： An improved assay for determining sensitivity to activated protein C in test samples has been developed to ensure rapid and accurate evaluations. This assay is based on measuring the conversion, by activated factor VIII within a test sample, of added factor X to an activated form. The activated protein C sensitivity of the test sample is determined by the relative inhibition of factor X conversion as compared to a control. A test sample that has decreased sensitivity to activated protein C will show relatively low inhibition, and vice versa.
摘要翻译： 已经开发了用于确定测试样品中对活化蛋白C的敏感性的改进测定法，以确保快速和准确的评估。 该测定法是基于测试样品中活化因子VIII的转化，将添加的因子X转化为活化形式。 与对照相比，测试样品的活化蛋白C敏感性由因子X转化的相对抑制决定。 对活化蛋白C的敏感性降低的测试样品将显示相对较低的抑制作用，反之亦然。
-
公开(公告)号：US6068838A
公开(公告)日：2000-05-30
申请号：US656589
申请日：1996-05-31
IPC分类号： A61K31/00 , A61K38/00 , A61K38/46 , A61P7/00 , A61P7/02 , A61P7/04 , C07K14/755 , C07K16/18 , C12N9/64 , C12Q1/37 , A61K38/48 , C12N9/48 , C12N9/50
CPC分类号： C07K14/755 , C12N9/6421 , A61K38/00 , Y10S435/814
摘要： There is disclosed a purified multimerase having an indirect and a direct proteolytic activity, which converts vWF having a singlet structure to vWF having a satellite structure and is active in the presence of the serine protease inhibitor DFP or the calpain protease inhibitor Z-Leu-Leu-Tyr-CHN.sub.2, as well as a method of preparing the multimerase according to the invention.
摘要翻译： 公开了具有间接和直接蛋白水解活性的纯化多聚甲基化酶，其将具有单重结构的vWF转化为具有卫星结构的vWF，并且在丝氨酸蛋白酶抑制剂DFP或钙蛋白酶蛋白酶抑制剂Z-Leu-Leu的存在下是有活性的 -Tyr-CHN2，以及制备根据本发明的多聚体酶的方法。
-
公开(公告)号：US5804159A
公开(公告)日：1998-09-08
申请号：US663031
申请日：1996-06-07
申请人： Johann Eibl , Peter Turecek , Hans Peter Schwarz
发明人： Johann Eibl , Peter Turecek , Hans Peter Schwarz
摘要： There is disclosed an anti-plasma antibody preparation for treatment of a mammal, which preparation is capable of directly or indirectly inhibiting and/or eliminating several blood factors, a method of producing such a preparation and a method of evaluating substances for treating clotting disorders by using said anti-plasma antibody preparation. There is further disclosed a method of determining the bleeding characteristics of a mammal.
摘要翻译： 公开了一种用于治疗哺乳动物的抗血浆抗体制剂，该制剂能够直接或间接地抑制和/或消除多种血液因子，制备这种制剂的方法和评估用于治疗凝血障碍的物质的方法通过 使用所述抗血浆抗体制剂。 还公开了确定哺乳动物的出血特征的方法。
-
公开(公告)号：US5698677A
公开(公告)日：1997-12-16
申请号：US435128
申请日：1995-05-05
IPC分类号： A61K9/127 , A61K9/14 , A61K38/43 , A61K38/48 , A61K38/55 , A61P7/02 , C12N9/64 , C12N9/96 , A61K35/14
CPC分类号： C12N9/96 , A61K38/4846 , A61K38/4866 , A61K9/127 , C12N9/6424 , C12N9/647 , C12Y304/21006 , C12Y304/21021 , C12Y304/21069
摘要： The invention relates to a stable preparation which comprises a protein that is bound in and/or on lipid vesicles and that was treated for the inactivation of potentially present viruses. Further, the invention relates to methods for the production of a stable preparation for the treatment of blood coagulation disorders, wherein a protein is bound in and/or on lipid vesicles, and the method comprises a step in which the protein lipid complex is subjected to a treatment for the inactivation of potentially present viruses.
摘要翻译： 本发明涉及一种稳定的制剂，其包含结合于脂质囊泡中和/或脂质囊泡上的蛋白质，并且被处理用于灭活潜在的存在的病毒。 此外，本发明涉及生产用于治疗凝血障碍的稳定制剂的方法，其中蛋白质与脂质囊泡中和/或结合，该方法包括将蛋白质脂质复合物经受 用于灭活潜在存在的病毒的治疗。
-
7.发明授权Pharmaceutical preparation containing protein C and a thrombolytically active substance 失效含有蛋白C和血栓溶解活性物质的药物制剂公开(公告)号：US06403556B1
公开(公告)日：2002-06-11
申请号：US07899866
申请日：1992-06-17
IPC分类号： A01N3718
CPC分类号： C07K14/3153 , A61K38/00 , C12N9/6435 , C12N9/6456 , C12N9/6459 , C12N9/6462 , C12N9/6464 , C12Y304/21007 , C12Y304/21068 , C12Y304/21069 , C12Y304/21073 , Y10S514/802 , Y10S514/822 , Y10S514/834
摘要： A pharmaceutical preparation contains protein C and a thrombolytically active substance that does not activate protein C. This preparation prevents reocclusion usually occurring in the course of thrombolysis therapy.
摘要翻译： 药物制剂含有蛋白质C和不激活蛋白质C的血栓溶解活性物质。该制剂防止通常在溶栓治疗过程中发生再闭塞。
-
公开(公告)号：US6017891A
公开(公告)日：2000-01-25
申请号：US924533
申请日：1997-09-05
CPC分类号： B82Y5/00 , C12N9/6424 , C12N9/96
摘要： The invention relates to a stable preparation which comprises a protein, such as thrombin, that is bound in and/or on (i.e., to) lipid vesicles and that was treated for the inactivation of potentially present viruses. Further, the invention relates to methods for the production of a stable preparation for the treatment of blood coagulation disorders, wherein a protein is bound in and/or on lipid vesicles, and the method comprises a step in which the protein lipid complex is subjected to a treatment for the inactivation of potentially present viruses.
摘要翻译： 本发明涉及一种稳定的制剂，其包含结合于脂质囊泡中和/或上（即）脂质囊泡上的蛋白质，例如凝血酶，并且被处理用于灭活潜在的存在的病毒。 此外，本发明涉及生产用于治疗凝血障碍的稳定制剂的方法，其中蛋白质与脂质囊泡中和/或结合，该方法包括将蛋白质脂质复合物经受 用于灭活潜在存在的病毒的治疗。
-
公开(公告)号：US5830467A
公开(公告)日：1998-11-03
申请号：US456684
申请日：1995-06-01
IPC分类号： A61K38/43 , A61K38/00 , A61K38/16 , A61K38/46 , A61K38/48 , A61K38/49 , A61P7/02 , C07K14/315 , C12N9/64 , C12N9/68 , C12N9/72 , C12N9/48 , C12N9/70
CPC分类号： C07K14/3153 , C12N9/6435 , C12N9/6456 , C12N9/6459 , C12N9/6462 , C12N9/6464 , C12Y304/21007 , C12Y304/21068 , C12Y304/21069 , C12Y304/21073 , A61K38/00 , Y10S514/802 , Y10S514/822 , Y10S514/834
摘要： A pharmaceutical preparation contains protein C and a thrombolytically active substance that does not activate protein C. This preparation prevents reocclusion usually occurring in the course of thrombolysis therapy.
-
公开(公告)号：US5776452A
公开(公告)日：1998-07-07
申请号：US410766
申请日：1995-03-27
CPC分类号： A61K38/166 , A61K38/484 , A61K38/49 , C12Y304/21007 , C12Y304/21068
摘要： The invention provides compositions having thrombolytic effects, and comprise plasmin and a plasminogen activator. Such compositions can be administered locally or systemically. The invention also provides simple and safe therapies for thrombotic states and prevention of such states.
摘要翻译： 本发明提供具有溶栓作用的组合物，并且包括纤溶酶和纤溶酶原激活剂。 这样的组合物可以局部或全身施用。 本发明还提供用于血栓形成状态的简单和安全的治疗方法以及预防这些状态。
-
-
-
-
-
-
-
-
-
搜索结果
11 条记录 (耗时 0.021 秒)